4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of “Moderate Buy” from Brokerages

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $40.60.

A number of equities research analysts recently issued reports on the stock. The Goldman Sachs Group reaffirmed a “buy” rating and set a $81.00 price target on shares of 4D Molecular Therapeutics in a research note on Wednesday, February 7th. Jefferies Financial Group increased their price target on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the company a “buy” rating in a research report on Monday, April 1st. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday, March 1st. Royal Bank of Canada raised their price target on shares of 4D Molecular Therapeutics from $25.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Finally, BMO Capital Markets lowered their target price on shares of 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating on the stock in a research note on Monday, April 1st.

Insiders Place Their Bets

In other news, CEO David Kirn sold 5,696 shares of the firm’s stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $18.41, for a total transaction of $104,863.36. Following the transaction, the chief executive officer now directly owns 1,151,154 shares of the company’s stock, valued at $21,192,745.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Scott Bizily sold 6,244 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $27.50, for a total value of $171,710.00. Following the completion of the transaction, the insider now owns 1,737 shares in the company, valued at approximately $47,767.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO David Kirn sold 5,696 shares of the stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $18.41, for a total value of $104,863.36. Following the completion of the transaction, the chief executive officer now owns 1,151,154 shares of the company’s stock, valued at approximately $21,192,745.14. The disclosure for this sale can be found here. Insiders have sold 147,888 shares of company stock valued at $4,134,254 over the last three months. Company insiders own 10.70% of the company’s stock.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently bought and sold shares of FDMT. Bfsg LLC acquired a new stake in 4D Molecular Therapeutics during the 4th quarter worth about $30,000. International Assets Investment Management LLC acquired a new stake in 4D Molecular Therapeutics during the 3rd quarter worth about $36,000. US Bancorp DE boosted its position in 4D Molecular Therapeutics by 580.7% during the 4th quarter. US Bancorp DE now owns 1,797 shares of the company’s stock worth $36,000 after acquiring an additional 1,533 shares during the period. Lazard Asset Management LLC boosted its position in 4D Molecular Therapeutics by 44.2% during the 2nd quarter. Lazard Asset Management LLC now owns 2,190 shares of the company’s stock worth $38,000 after acquiring an additional 671 shares during the period. Finally, Ensign Peak Advisors Inc boosted its position in 4D Molecular Therapeutics by 167.9% during the 3rd quarter. Ensign Peak Advisors Inc now owns 7,180 shares of the company’s stock worth $58,000 after acquiring an additional 4,500 shares during the period. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ FDMT opened at $28.60 on Monday. 4D Molecular Therapeutics has a 1 year low of $9.44 and a 1 year high of $36.25. The stock has a market cap of $1.42 billion, a P/E ratio of -10.75 and a beta of 2.87. The firm has a 50-day moving average of $28.37 and a 200 day moving average of $19.31.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Thursday, February 29th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.09). The firm had revenue of ($0.02) million during the quarter, compared to analysts’ expectations of $4.67 million. 4D Molecular Therapeutics had a negative return on equity of 34.14% and a negative net margin of 436.30%. Research analysts expect that 4D Molecular Therapeutics will post -3.03 earnings per share for the current fiscal year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.